Redeye comments on yesterday’s Key Opinion Leader (KOL) event, which focused heavily on the biology ...
JonDeTech är ett svenskt deep-tech-bolag som utvecklar och kommersialiserar en ny generation tunna o...
Redeye updates its view on Biovica following a Q4 2025/2026 report that aligned with our expectation...
We lower our DCF fair value range to SEK 103-146 following Duni’s profit warning.
Redeye views Optomed’s cEUR1.8m order from a US-based screening service provider and distributor pos...
Redeye comments on the R&D presentation related to SAN2668 from last week.
Yesterday, NanoRepro announced the conversion of a distribution license covering a CGM-technology of...
Tonies held its first-ever Capital Markets Day, announcing an upbeat mid-term margin and growth guid...
Redeye briefly comments on Snark BidCo (Altor) extending its acceptance period for Sleep Cycle until...
Redeye is bullish on Medivir’s directed share issue of SEK140m.
Redeye is positive about the acquisition of Rosetta Capital’s shares in the investment vehicle KDev ...
The trend of a healthy lifestyle enjoys a sustainably growing attraction across all age groups.
Flughafen Wien’s May traffic data were better than feared and support our positive stance on the sto...
LIMES signed a preliminary yet binding agreement to acquire the operating company of the “Villa Bocc...
Solwers estimates that its performance in H1 2026 has developed weaker than expected and withdraws i...
On 18 November 2025, Mendus entered into a loan facility with Fenja (of SEK 50m in total).
SynAct has reported top-line results from its Phase IIb ADVANCE study evaluating resomelagon in newl...
Director of M&A and Business Development, Sebastian Seppänen, has been appointed as interim CFO of R...
B&C raised its stake by 6.1pp to 63.4% via a € 15/share offer.
GFT’s quality banking IT franchise, AI-enabled project expansion and UK/smartshore margin levers rem...